Novo Nordisk’s Positive Q4 Update Highlights Pipeline Plans
Once-Weekly Basal Insulin LAI287 Successfully Passed Phase II Trial
Executive Summary
Novo Nordisk used a solid Q4 update to confirm it will progress its investigative once-weekly basal insulin to Phase III.